- 1 Trends and spatial distribution of pneumonia admissions and deaths among
- 2 children <5 years, Uganda, 2013-2021
- 3 Mercy Wendy Wanyana^{1*}, Richard Migisha¹, Patrick King¹, Lilian Bulage¹, Benon
- 4 Kwesiga¹, Daniel Kadobera¹, Alex Riolexus Ario^{1,2}, Julie R. Harris³
- ¹Uganda Public Health Fellowship Program, Uganda National Institute of Public Health,
- 6 Kampala, Uganda

9

- ²Ministry of Health, Kampala, Uganda
- 8 ³US Centers for Disease Control and Prevention, Kampala, Uganda
- *Correspondence: Mercy Wendy Wanyana, +256779207928, mwanyana@uniph.go.ug
- 11 Target Journal: BMC Pneumonia
- 12 Abstract word limit: 350
- 13 Abstract word count: 333
- 14 Body word limit: 3500
- 15 Body word count: 2250
- 16 Tables limit: 5
- 17 Tables count: 4
- 18 Figures limit: 5
- 19 Figures count: 2

Abstract

- 22 Background: Pneumonia is the second leading cause of hospital admissions and
- 23 deaths among children <5 years old in Uganda. In 2013, Uganda adopted various
- interventions to protect, prevent, and improve the treatment of pneumonia under the
- 25 Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea (GAPPD),
- including the introduction of the pneumococcal conjugate vaccine (PCV) into routine
- immunization schedule. However, little is known about the impact of these interventions
- on pneumonia admissions and deaths. We described the trends and spatial distribution
- of pneumonia hospital admissions and mortality among children <5 years in Uganda,
- 30 2013–2021.
- Methods: We analysed secondary data on pneumonia admissions and deaths from the
- District Health Information System version 2 during 2013–2021. Reporting rates were
- calculated as the percentage of expected complete monthly health facility reports
- submitted to the national surveillance database. The proportion of pneumonia cases
- admitted and case-fatality rates (CFRs) for children <5 years were calculated for
- children <5 years presenting at the outpatient department. At national, regional, and
- district levels, pneumonia mortality rates were calculated per 100,000 children <5 years.
- The Mann-Kendall Test was used to assess trend significance.
- Results: There were 753,978 pneumonia admissions and 13,632 (2%) deaths during
- 40 2013–2021. Reporting rates ranged from 78–92%. The overall proportion of pneumonia
- cases admitted among children <5 years was 23%. The overall CFR was 0.41%, and
- the overall pneumonia mortality rate among children <5 years was 21 deaths per
- 43 100,000. From 2013 to 2021, there were declines in the proportion of pneumonia cases
- admitted (33% to 15%; p=0.051), mortality rates (26/100,000 to 13 per 100,000;
- 45 p=0.01), and CFR (0.61% to 0.24%; p=0.01), concomitant with increasing PCV
- 46 coverage. Kotido District had a persistently high proportion of pneumonia cases that
- were admitted (>30%) every year while Kasese District had persistently high mortality
- 48 rates (68-150 deaths per 100,000 children <5 years).
- 49 **Conclusion:** Pneumonia admissions, mortality, and case fatality among children <5
- years declined during 2013–2021 in Uganda after the introduction of PCV. However,
- with these trends it is unlikely that Uganda will meet the 2025 GAPPD targets. There is
- therefore a need to review implementation of existing interventions, identify gaps in
- order to highlight priority actions to further accelerate declines.
- Keywords: Pneumonia admission, Mortality, Children, Uganda

Background

56

In 2019, pneumonia was the leading infectious cause of death globally among children 57 <5 years old, accounting for 14% of all deaths in this age group¹. Half of the pneumonia 58 cases and deaths among children <5 years are reported in sub-Saharan Africa². 59 Worldwide, pneumonia in childhood is commonly caused by *Streptococcus* 60 pneumoniae³. The pneumococcal conjugate vaccine (PCV) contains serotypes that are 61 commonly associated with invasive and mucosal pneumonia among children <5 years 62 and can reduce both incidence and severity of disease⁴. While pneumonia incidence 63 among children <5 years declined globally during 2000 to 2015, the same time period 64 saw an increase in pneumonia requiring admissions in sub-Saharan Africa^{2,5}. 65 In Uganda, pneumonia is the second leading cause of all hospital admissions among 66 children <5 years⁶, most of which is caused by *Streptococcus pneumoniae*⁷. To reduce 67 this burden, Uganda and other low-income countries committed in 2013 to implementing 68 the World Health Organization's integrated Global Action Plan for the Prevention and 69 Control of Pneumonia and Diarrhoea (GAPPD)⁸. This initiative included the introduction 70 of the 10-valent PCV (PCV10) into the routine immunisation schedule. PCV10 targets 71 the commonest pneumococcal serotypes documented in Uganda before its introduction 72 (6B,19F, and 23F) as well as serotypes 1, 4, 5, 7F,9V,14, and 18C^{9,10}. Three doses of 73 PCV10 (PCV1, 2, and 3) are given to children at 6, 10, and 12 weeks of age¹¹. Other 74 low-cost interventions put in place with GAPPD include exclusive breastfeeding for the 75 first six months and continued breastfeeding with appropriate complementary feeding 76 thereafter; use of simple, standardized guidelines for the identification and treatment of 77 pneumonia in the community through integrated community case management of 78 79 childhood illnesses; and reduction of household air pollution with improved stoves⁸. With 80 these interventions, implemented in 2013, Uganda is attempting to reduce the incidence of pneumonia requiring admission by 75% in children <5 years from 2013 to 2025 and 81 reduce mortality from pneumonia in children <5 years of age to <3 per 1,000 live births 82 by 2025. 83 84 Currently, little is documented on Uganda's progress towards these goals. Previous studies conducted in Uganda assessed the prevalence of pneumonia at specific 85

timepoints and may not reflect Uganda's progress over time^{12,13}. Additionally, these studies were conducted in sub-regions and may not be generalisable to the entire country or show meaningful spatial differences. We assessed the temporal trends and spatial distribution of pneumonia admissions and mortality among children <5 years in Uganda from 2013–2021 to assess progress towards these goals.

Methods

92

120

Study setting 93 We utilized pneumonia data generated from all health facilities in Uganda. The Uganda 94 95 health system classifies health facilities into various levels based on their capacities. In Uganda, outpatient pneumonia cases are managed at all levels, while those with 96 97 pneumonia requiring admission are managed at health centres III and IV, general and regional referral hospitals, and national referral hospitals, all of which have in-patient 98 services¹⁴. Patients are also referred as needed from lower-level facilities (health 99 centres) to higher-level facilities (hospitals). 100 101 Data source We conducted a descriptive study using routinely-collected pneumonia surveillance data 102 from the District Health Information System version 2 (DHIS2) during 2013–2021. 103 DHIS2 is an electronic database that was officially adopted in 2012¹⁵. It contains data 104 on priority diseases, conditions, and events of public health importance, including 105 pneumonia from 2013 to-date¹⁶. Aggregate data on pneumonia cases, admissions, and 106 deaths from both outpatient and inpatient monthly reports (Health Management 107 Information System forms [HMIS] 105 and HMIS 108) from 2013–2021 were used for 108 this study. 109 Study variables, data management, and analysis 110 We obtained aggregate data on pneumonia cases and admissions among children <5 111 years to calculate the annual proportion of pneumonia cases admitted. A pneumonia 112 admission was defined as a hospital stay in a person with pneumonia as a primary 113 diagnosis, based on the International Classification of Disease-10 framework. A 114 115 pneumonia case at the outpatient department was defined as pneumonia as a primary diagnosis based on the International Classification of Disease-10 framework in a patient 116 not requiring a hospital stay. We calculated the proportion of pneumonia cases admitted 117 using pneumonia admissions <5 years as a numerator and total pneumonia cases <5 118 years presenting at the outpatient department as a denominator. (All admitted patients 119

with pneumonia pass through the outpatient department before admission.) Pneumonia

deaths were defined as in-patient deaths with pneumonia recorded as the primary cause of death. We calculated pneumonia mortality using pneumonia deaths among children <5 years as a numerator and estimated annual population data for children <5 years from the Uganda Bureau of Statistics (UBOS) as a denominator. Case-fatality rates (CFRs) were calculated as the proportion of pneumonia cases <5 years at health facilities who died at the facility. Reporting rates for cases and deaths were calculated as the percentage of the expected monthly reports that were submitted to DHIS2 from 2013 to 2021. PCV 3 vaccine coverage was calculated as the percentage of the target population who received 3 doses of the PCV10 in a given year based on data obtained from DHIS2. Although the PCV10 vaccine was introduced in 2013, official rollout to the entire country started in 2014¹⁷. PCV 3 vaccine coverage was therefore calculated from 2014 to 2021. We downloaded data in Excel and imported it into Epilnfo 7 software (CDC, Atlanta, USA) for analysis. Annual proportion of pneumonia cases admitted, mortality rates, and case-fatality rates were calculated at national and regional levels. Line graphs were used to describe national and regional trends. The Mann-Kendall test was conducted to assess significance of the trends. Choropleth maps drawn using QGIS software were used to show the spatial distribution of pneumonia admissions and mortality in the country. **Ethical Considerations** Our study utilized routinely generated aggregated surveillance data with no personal identifiers in health facility in-patient monthly reports through the DHIS2. The Ministry of Health (MoH) of Uganda through the office of the Director General Health Services gave approval to access data from the DHIS2. We stored the abstracted data set in a password-protected computer and only shared it with the investigation team. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.§ §See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

Results National trends in the proportion of pneumonia cases admitted among children <5 years with pneumonia in Uganda, 2013-2021 During the study period, reporting rates for both admissions and deaths increased from 78% to 92% (Kendall's score=24, p=0.017). There was a total of 3,560,974 outpatient pneumonia cases and 753,978 admitted pneumonia cases reported among children <5 years. The overall proportion of pneumonia cases <5 years admitted was 21% (range: 15-34%). Overall, there was a 50% decline in the proportion of pneumonia cases admitted over the study period, from 30% to 15% (Kendall's score=-20, p=0.051), concurrent with increasing PCV 3 vaccine coverage from 60% to 91% (Figure 1). National trends in pneumonia mortality among children <5 years, Uganda, 2013-2021 During the study period, there were 13,632 pneumonia-related deaths among children <5 years. The overall pneumonia mortality rate was 21 deaths per 100,000 children <5 years (Figure 2). There was a 50% decline in pneumonia mortality rates from 26 to 13 per 100,000 children <5 years (Kendall's score = -14, p=0.005). Pneumonia case-fatality rate among children <5 years, Uganda, 2013–2021 The overall CFR was 0.41% children <5 years with pneumonia (Range: 0.25–0.69). There was a 61% decline from 0.61% to 0.24% over the evaluation period (Kendall's score = -26, p=0.009) (Figure 3). Regional trends of pneumonia cases admitted, mortality rate and case fatality rate among children <5 years, Uganda, 2013-2021 Both the proportion of pneumonia cases admitted and pneumonia mortality rates among children <5 years were higher in the Northern Region than in the Western, Eastern, and

Central Regions (Table 1). Case-fatality rates were higher in the Central, Northern, and 178 Western regions than in the Eastern Region. Declines in mortality rates were observed 179 180 over the study period across all regions, while case-fatality rates declined in the Northern and Western regions (Table 1). 181 Spatial distribution of proportion of pneumonia cases admitted and mortality 182 among children <5 years, Uganda, 2013-2021 183 184 Proportion of pneumonia cases among children <5 years that were admitted was generally highest in north-eastern Uganda. Kotido District had consistently high 185 admissions rates of >40% throughout the study period (Figure 4). 186 Kasese District (Figure 5) had consistently high pneumonia mortality throughout the 187 review period ranging from 68 to 150 deaths per 100,000 children <5 years. 188 189

Discussion

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

We described the trends and spatial distribution of pneumonia hospital admissions, mortality, and case-fatality among children <5 years in Uganda from 2013–2021. Over the 9 years, there was a decline in both the proportion of pneumonia cases that were admitted and deaths concomitant with an increase in PCV3 coverage. After the introduction of PCV10 in Uganda in 2013, we found a ≥50% reduction in pneumonia cases admitted, mortality, and case-fatality rates among children <5 years over the next 9 years. These findings are in agreement with those in other African countries after PCV was introduced: a study in Burkina Faso identified a 34% reduction in pneumonia admissions among children <5 years five years after the introduction of PCV¹⁸, while another in Zambia found a 38% and 29% decline in pneumonia admissions among children aged <1 year and 1–4 years, respectively, three years after introduction of PCV¹⁹. Studies in South Africa and Rwanda have had similar findings²⁰,²¹. The greater reductions in our study, compared to the others, could be related to the longer period of observation after the introduction of PCV in our study. Declines in admissions and case fatality rates observed in 2015 could also be attributable to the impact of the WHO-recommended admission criteria introduced in 2014²². Before 2014, any child <5 years old with pneumonia (i.e., with fast breathing and/or chest indrawing) was recommended to be admitted. With the revisions in 2014, recommendations for admission were changed to pneumonia plus any danger signs, which would have led to declines in admissions. The revised treatment guidelines promoted outpatient treatment of pneumonia without danger signs with oral amoxicillin. This was a more effective and accessible treatment, and has been linked to a reduction in pneumonia deaths among children²². We noted that the largest decline in case-fatality rates occurred from 2015 to 2016. It is unknown why this occurred, but it may be related to the 32% decline in new HIV infections between 2014 and 2015, which represented the largest decline in many years²⁶. HIV is a key risk factor for pneumonia deaths among children <5 years linked and is associated with a 4-fold increased risk of pneumonia death²⁷. Additional declines in pneumonia case-fatality rates even after 2015 might also reflect improvements in the

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

quality of healthcare during the study period. Integrated community case management introduced at the start of the review period facilitated prompt diagnosis and access to antibiotics at the community level, improving appropriate care-seeking²³. During the review period, there were also increases in access to electricity (both hydroelectricity and solar), especially at low-level health facilities over time, there is increased access to oxygen therapy thereby improving patient survival thus reducing case-fatality rates^{24,25}. The 50% decline in pneumonia admissions over the 9-year period was borderline significant, suggesting a smaller effect of the PCV on pneumonia admissions than on mortality or case-fatality²⁸. While PCV reduces the severity and incidence of pneumonia among the strains it targets²⁹, previous studies have shown that the introduction of PCV can lead to an increase in the proportion of pneumococcal pneumonia due to nonvaccine pneumococcal serotypes^{30,31}. It is possible that in Uganda, like other African countries, other serotypes are taking the place of those targeted by PCV. A study in the Gambia indicated a 47% increase in pneumococcal pneumonia due to non-vaccine serotypes 3 years following PCV13 introduction³². Similarly, a 27% increase in pneumococcal pneumonia was observed in Botswana following introduction of PCV³³. However, there are few data available on the current distribution of circulating serotypes in Uganda. The decline suggests that Uganda may be on track to reach the GAPPD target of a 75% reduction in admissions by 2025. Nonetheless, monitoring of trends in the circulating pneumococcal serotypes in the post-PCV era and maintaining other interventions to reduce the burden and impact of childhood pneumonia is important to ensuring that the reductions continue³⁴. Regional variations in the proportion of pneumonia cases admitted, pneumonia mortality, and case-fatality rates were observed. The highest proportion of pneumonia cases admitted and mortality were observed in the northern and eastern regions. These regions are characterised with higher levels of poverty and poor housing compared to other areas of the country, which are known to be associated with increased likelihood of pneumonia requiring admission and mortality^{35,36}. There is a need to understand the factors associated with high burden of severe pneumonia in these regions to develop targeted interventions.

Our findings should be interpreted with the following limitations. We used inpatient data, which could lead to underestimation of the true pneumonia mortality by missing cases and deaths that occurred in communities. Secondly, we used aggregated secondary data, which lacked key variables to further explore trends across subcategories within this age group. Thirdly, we were unable to make before-and-after PCV10 comparisons of pneumonia admissions and deaths due to the lack of data before PCV10 introduction. As a result, we cannot assess the impact of the introduction of PCV10 on the observed trends of pneumonia admissions and deaths to the interventions introduced in 2013. Finally, despite reductions in pneumonia admissions and deaths with increasing PCV10 coverage, we cannot definitively attribute these reductions to PCV10. During this time period, other interventions, including exclusive breastfeeding for the first six months and continued breastfeeding with appropriate complementary feeding thereafter, increased access to antibiotics through integrated community case management of childhood illnesses, reduction of household air pollution with improved stoves, and increased access to oxygen therapy were implemented, and these also likely led to reductions.

Conclusion

- Our findings demonstrate declines in pneumonia admissions, mortality rates, and case-
- 268 fatality rates among children <5 years over the 9-year period following the introduction
- of PCV in Uganda. However, with these trends it is unlikely that Uganda will meet the
- 2025 targets. Reviewing the implementation of existing interventions and identification
- of gaps to highlight priority actions could further accelerate decline.
- 272 List of abbreviations
- **DHIS2:** District Health Information System version 2
- **GAPPD:** Global Action Plan for the Prevention and Control of Pneumonia and
- 275 Diarrhoea
- 276 HC: Health Centre
- **HMIS**: Health Management Information System
- **PCV:** Pneumococcal Conjugate Vaccine
- **UBOS:** Uganda Bureau of Statistics

Acknowledgements

We would like to thank the Ministry of Health for providing access to DHIS2 data that was used for this analysis. We appreciate the technical support provided by the Division of Surveillance, Information and Knowledge Management, MoH. Finally, we thank the US-CDC for supporting the activities of the Uganda Public Health Fellowship Program.

References

- Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet Child Adolesc Heal. 2022 Feb;6(2):106–15.
- Troeger CE, Khalil IA, Blacker BF, Biehl MH, Albertson SB, Zimsen SRM, et al. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis [Internet]. 2020 Jan 1;20(1):60–79. Available from: https://doi.org/10.1016/S1473-3099(19)30410-4
- O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al.
 Burden of disease caused by Streptococcus pneumoniae in children younger than
 5 years: global estimates. Lancet (London, England). 2009 Sep;374(9693):893–
 902.
- Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2000 Jan;30(1):100–21.
- McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. Lancet Glob Heal. 2019 Jan;7(1):e47–57.
- MoH M of HU. Ministry of Health Annual Sector Performance Report 2020/2021
 [Internet]. Kampala, Uganda; 2021. Available from:
 http://library.health.go.ug/publications/performance-management/annual-health-sector-performance-report-financial-year-202021
- 7. Nantanda R, Hildenwall H, Peterson S, Kaddu-Mulindwa D, Kalyesubula I,
 Tumwine JK. Bacterial aetiology and outcome in children with severe pneumonia in Uganda. Ann Trop Paediatr. 2008 Dec;28(4):253–60.
- WHO (World Health Organisation). Ending preventable child deaths from pneumonia and diarrhoea by 2025: the integrated global action plan for pneumonia and diarrhoea (GAPPD). 2013;
- Lindstrand A, Kalyango J, Alfvén T, Darenberg J, Kadobera D, Bwanga F, et al.
 Pneumococcal Carriage in Children under Five Years in Uganda-Will Present
 Pneumococcal Conjugate Vaccines Be Appropriate? PLoS One.
 2016;11(11):e0166018.
- Nackers F, Cohuet S, le Polain de Waroux O, Langendorf C, Nyehangane D, Ndazima D, et al. Carriage prevalence and serotype distribution of Streptococcus pneumoniae prior to 10-valent pneumococcal vaccine introduction: A population-based cross-sectional study in South Western Uganda, 2014. Vaccine [Internet]. 2017;35(39):5271–7. Available from:

- https://www.sciencedirect.com/science/article/pii/S0264410X17310071
- 11. MoH (Minstry of Health Uganda). Routine Immunisation Question and Answer Booklet [Internet]. Kampala, Uganda; 2013. Available from:
- https://www.unicef.org/uganda/media/2776/file/Routine Immunisation Q & A booklet.pdf
- 12. Kiconco G, Turyasiima M, Ndamira A, Yamile OA, Egesa WI, Ndiwimana M, et al. Prevalence and associated factors of pneumonia among under-fives with acute respiratory symptoms: a cross sectional study at a Teaching Hospital in Bushenyi District, Western Uganda. Afr Health Sci. 2021 Dec;21(4):1701–10.
- Ma C, Gunaratnam LC, Ericson A, Conroy AL, Namasopo S, Opoka RO, et al.
 Handheld Point-of-Care Lactate Measurement at Admission Predicts Mortality in
 Ugandan Children Hospitalized with Pneumonia: A Prospective Cohort Study. Am
 J Trop Med Hyg. 2019 Jan;100(1):37–42.
- 14. IHE (Institute for Health Metrics and Evaluation). Assessing Facility Capacity,
 Costs of Care, and Patient Perspectives [Internet]. Seattle; Available from:
 https://www.healthdata.org/sites/default/files/files/policy_report/2014/ABCE/Ugand
 a/ABCE_Uganda_full_report_2014.pdf
- 15. Kiberu VM, Matovu JKB, Makumbi F, Kyozira C, Mukooyo E, Wanyenze RK.
 Strengthening district-based health reporting through the district health
 management information software system: the Ugandan experience. BMC Med
 Inform Decis Mak [Internet]. 2014;14(1):40. Available from:
 https://doi.org/10.1186/1472-6947-14-40
- MoH (Minstry of Health Uganda). National Technical Guidelines for Integrated
 Disease Surveillance and Response Third Edition [Internet]. 2021. Available from:
 https://www.afro.who.int/sites/default/files/2021-09/2_Uganda 3rd IDSR Tech
 Guideline_PrintVersion_10Sep2021.pdf
- WHO (World Health Organisation). Uganda rolls out the Pneumococcal Conjugate
 Vaccine (PCV) [Internet]. 2014 [cited 2023 Dec 2]. Available from:
 https://www.afro.who.int/news/uganda-rolls-out-pneumococcal-conjugate-vaccine-pcv
- 18. Kaboré L, Ouattara S, Sawadogo F, Gervaix A, Galetto-Lacour A, Karama R, et al. Impact of 13-valent pneumococcal conjugate vaccine on the incidence of hospitalizations for all-cause pneumonia among children aged less than 5 years in Burkina Faso: An interrupted time-series analysis. Int J Infect Dis [Internet]. 2020 Jul 1;96:31–8. Available from: https://doi.org/10.1016/j.ijid.2020.03.051
- Mpabalwani EM, Lukwesa-Musyani C, Imamba A, Nakazwe R, Matapo B,
 Muzongwe CM, et al. Declines in Pneumonia and Meningitis Hospitalizations in
 Children Under 5 Years of Age After Introduction of 10-Valent Pneumococcal
 Conjugate Vaccine in Zambia, 2010–2016. Clin Infect Dis [Internet]. 2019 Sep
 5;69(Supplement_2):S58–65. Available from: https://doi.org/10.1093/cid/ciz456
- 368 20. Kleynhans J, Tempia S, Shioda K, von Gottberg A, Weinberger DM, Cohen C.

- Estimated impact of the pneumococcal conjugate vaccine on pneumonia mortality in South Africa, 1999 through 2016: An ecological modelling study. PLOS Med
- 371 [Internet]. 2021 Feb 16;18(2):e1003537. Available from:
- 372 https://doi.org/10.1371/journal.pmed.1003537
- 21. Rurangwa J, Rujeni N. Decline in Child Hospitalization and Mortality After the Introduction of the 7-Valent Pneumococcal Conjugative Vaccine in Rwanda. Am J Trop Med Hyg. 2016 Sep;95(3):680–2.
- WHO (World Health Organisation). Revised who classification and treatment of childhood pneumonia at health facilities, 2014. Geneva WHO. 2021;
- Kalyango JN, Alfven T, Peterson S, Mugenyi K, Karamagi C, Rutebemberwa E. Integrated community case management of malaria and pneumonia increases prompt and appropriate treatment for pneumonia symptoms in children under five years in Eastern Uganda. Malar J [Internet]. 2013;12(1):340. Available from: https://doi.org/10.1186/1475-2875-12-340
- Khogali A, Ahmed A, Ibrahim M, Karrar K, Elsheikh M, Abdelraheem E, et al.
 Building power-ful health systems: the impacts of electrification on health
 outcomes in LMICs. Psychol Health Med [Internet]. 2022 Dec 15;27(sup1):124–
 Available from: https://doi.org/10.1080/13548506.2022.2109049
- Turnbull H, Conroy A, Opoka RO, Namasopo S, Kain KC, Hawkes M. Solar-powered oxygen delivery: proof of concept. Int J Tuberc lung Dis Off J Int Union against Tuberc Lung Dis. 2016 May;20(5):696–703.
- 26. Uganda AIDS Commission. The Uganda HIV and AIDS country progress report
 July 2015-June 2016.
- Wilkes C, Bava M, Graham HR, Duke T. What are the risk factors for death among children with pneumonia in low- and middle-income countries? A systematic review. J Glob Health. 2023 Feb;13:5003.
- Hackshaw A, Kirkwood A. Interpreting and reporting clinical trials with results of borderline significance. BMJ [Internet]. 2011 Jul 4;343:d3340. Available from: http://www.bmj.com/content/343/bmj.d3340.abstract
- Reyburn R, Tsatsaronis A, von Mollendorf C, Mulholland K, Russell FM.
 Systematic review on the impact of the pneumococcal conjugate vaccine ten
 valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed
 and severe pneumonia hospitalisation rates and pneumonia mortality in children
 0-9 years old. J Glob Health. 2023 Feb;13:5002.
- 403 30. Masomian M, Ahmad Z, Gew LT, Poh CL. Development of Next Generation
 404 Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines.
 405 2020 Mar;8(1).
- 406 31. Ali MA, Okojokwu OJ, Adiekwuo RC, Robinson JW. Prevalence and serotypes of Streptococcus pneumoniae among under five children attending Toro general hospital, Bauchi State, Nigeria. Microbes Infect Dis [Internet]. 2023;4(2):468–76.

409 Available from: https://mid.journals.ekb.eg/article 240662.html

- Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive
- pneumococcal disease in The Gambia: a population-based surveillance study.
- 413 Lancet Infect Dis. 2016 Jun;16(6):703–11.

- 414 33. Patel SM, Shaik-Dasthagirisaheb YB, Congdon M, Young RR, Patel MZ, Mazhani T, et al. Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine. PLoS One. 2022;17(1):e0262225.
- 418 34. Du Q, Shi W, Yu D, Yao K. Epidemiology of non-vaccine serotypes of
 419 Streptococcus pneumoniae before and after universal administration of
 420 pneumococcal conjugate vaccines. Hum Vaccin Immunother [Internet]. 2021 Dec
 421 2;17(12):5628–37. Available from:
 422 https://doi.org/10.1080/21645515.2021.1985353
- 423 35. Atamanov A, Malasquez Carbonel EA, Masaki T, Myers CA, Granguillhome
 424 Ochoa R, Sinha N. Uganda Poverty Assessment: Strengthening Resilience to
 425 Accelerate Poverty Reduction. 2022;
- 426 36. Azab SFAH, Sherief LM, Saleh SH, Elsaeed WF, Elshafie MA, Abdelsalam SM.
 427 Impact of the socioeconomic status on the severity and outcome of community428 acquired pneumonia among Egyptian children: a cohort study. Infect Dis Poverty
 429 [Internet]. 2014;3(1):14. Available from: https://doi.org/10.1186/2049-9957-3-14




Figure 1: National trend in proportion of pneumonia cases admitted among children <5 years with pneumonia, Uganda, 2013–2021; PCV: Pneumococcal conjugate vaccine. Data for 2013 were not available.





Figure 2: National trend in pneumonia mortality among children <5 years, Uganda, 2013–2021; PCV: Pneumococcal conjugate vaccine. Data for 2013 were not available.



medRxiv preprint on Imps://coi.org/10.116.7/2024.02.13.243(12/70), this version posted February 14, 2024. The copyright horse for this preprint Children < 5 years, (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is national is a S GA e ninest work lives not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.




Figure 4: Spatial distribution of proportion of pneumonia cases admitted among children <5 years, 2013-2021, Uganda




Figure 5: Spatial distribution of pneumonia mortality rate among children <5 years, 2013-2021, Uganda

Table 1: Regional trends of pneumonia cases admitted, mortality rate, and case fatality rate among children <5 years Uganda, 2013-2021. Kendall's score and p-value represents the presence or absence of a 9-year linear trend.

Region	Proportion of pneumonia cases admitted (%) children <5 years			Case-fatality rate %			Mortality rate Per 100,000 children <5 years		
	Annual	Kendall's	P-value	Annual	Kendall's	P-value	Annual	Kendall's	P-value
	Mean	Score		Mean	Score		Mean	Score	
Central	14.0	-4	0.70	0.49	-5	0.55	19	-18	0.03
Eastern	10.7	-11	0.71	0.33	-11	0.13	15	-20	0.05
Northern	28.8	1	0.99	0.49	-15	0.04	28	-30	0.003
Western reprint doi: https://doi.	21.3	-5	0.56	0.44	-15	0.04	21	-26	0.009

(which was not certified by beer review) is the author/funder, who has granted medRxiv a license to display the preprint in properties and its also made available for use under a CC0 license.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.13.24302770; this version posted February 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.